

# Anti-CALCA/CALCB (Eptinezumab), Humanized Antibody

09/20

---

**CATALOG NO.:** A2217-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a fully humanized monoclonal antibody that targets alpha and beta isoforms of calcitonin gene-related peptide (CALCA and CALCB). Calcitonin gene-related peptide (CGRP) is a neuropeptide that is released by the nerve endings of nociceptive (trigeminal) neurons. In addition to dilating meningeal vessels, CGRP causes extravasation of plasma protein and degranulation of mast cells. Degranulation of mast cells releases pro-inflammatory cytokines and causes neurogenic inflammation. Inflammation promotes sensitization of trigeminal neurons that carry the pain stimuli to the thalamus, hypothalamus, and cortex, thus resulting in migraine attacks. The antibody targets both CALCA and CALCB by inhibiting their binding to the receptor thus preventing migraine attacks. The original monoclonal antibody has been approved by the FDA to treat migraines in adults.

**ALTERNATE NAMES:** ALD403, CT, KC, PCT, CGRP, CALC1, CGRP1, CGRP-I, CGRP-alpha, CALC2, CGRP2, CGRP-II

**ANTIBODY TYPE:** Monoclonal

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human CALCA/CALCB

**CAS NUMBER:** 1644539-04-7

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-23α (Guselkumab), Human IgG1 Antibody (A2147)  
 Anti-CD20 (Ofatumumab), Human IgG1 Antibody (A2172)  
 Anti-IL-17Rα (Brodalumab), Human IgG2 Antibody (A2155)  
 Anti-CD22 (Inotuzumab Ozogamicin), Humanized Antibody (A2179)  
 Anti-IL-23α (Tildrakizumab), Humanized Antibody (A2159)

**FOR RESEARCH USE ONLY! Not to be used on humans.**